6/13/11 by Chris Goldstein –  A check with the NJ Department of Health and Human Services (DHSS) today revealed that ninety (90) physicians are currently registered in a unique program for medical marijuana. New Jersey is the first in the country to require that doctors complete special requirements and register with the state to recommend cannabis.

The scheme is following a set of regulations proposed by Governor Chris Christie’s administration. After eighteen months of steady delays, the rules have not been officially finalized. The NJ Legislature took the rare move to pass a resolution stating that the regulations are working against the intent of the compassionate use law.

Physicians around the state loudly criticized the registry that requires training in addictive medicines. The former DHSS Commissioner Dr. Poonam Alaigh testified before the NJ Senate Health Committee in March that there were no similar requirements for other drugs. This may explain why only 90 doctors out of more than 30, 000 who practice in New Jersey are participating in the medicinal marijuana program.

Under the extreme NJ regulations patients must have a registered doctor to begin the process of entering the cannabis program. The patient must also choose one of six Alternative Treatment Center (ATC) sites because they are not allowed to cultivate at home. Once the application is approved by DHSS the patient will be issued an ID card.

The number of registered medical marijuana patients in New Jersey is currently zero.  Although some multi-million dollar facilities have been approved there are none open. The ATCs are not even building their facilities after Governor Christie and state Attorney General Paula Dow started questioning the inherent (and legislatively approved) conflicts with federal law.

The New Jersey Compassionate Use Medical Marijuana Act was signed in January of 2010, a final act in Jon Corzine’s term as governor.  The Democrat Corzine lost a second term to Republican Chris Christie in a closely contested election. During a TV debate Christie, a former US Attorney (federal prosecutor), seemed to have a change of heart saying that he supported medical marijuana in “concept.”

But since gaining office Governor Christie has taken a harder line. This approach is leaving the patients of at least ninety specially qualified NJ physicians, approved under the strictest rules in the country, without legal access to a medical therapy they need.

Some potentially qualifying patients have struggled to find doctors already registered, but the list is not public. Even more of the local NJ patients say that they have given up on the program. They have cancer, Multiple Sclerosis, HIV or other serious conditions and access the ubiquitous underground marijuana market instead.

Therapeutic cannabis is only legal on paper in New Jersey and it may stay on the page for some time longer. Medical professionals, especially those in hospice care, can only have the personal compassion to fulfill the law – looking the other way as patients and their families risk arrest.

Grassroots link: The Coalition for Medical Marijuana New Jersey (CMMNJ)

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. Questions?  [email protected]

Empire State NORML logo

12/8/2011 – New York City has the distinction of performing more marijuana arrests than anywhere else in the country; over 50,000 each year. This is almost double the annual arrests in the entire state of New Jersey and flies in the face of a New York State decriminalization law passed in 1979.

Reuter’s news service and WNYC are reporting this week that NYC Police said that arrests have dropped since September when Police Commissioner Raymond Kelly addressed the issue within the department. Kelly’s move followed intense media coverage of the racial disparity to the arrests (more than 90% are men of color) and the overly-harsh consequences of a pot arrest such as loss of parental rights.

Reuters story:

New York City police made 1,190 fewer marijuana arrests since Commissioner Raymond Kelly’s September 19 directive, compared to the same nine-week period a year ago, spokesman Paul Browne said.

A coalition of groups that has criticized the police force for its aggressive approach to marijuana possession called the numbers a “disappointing drop” and said New York City remains the “marijuana arrest capital of the world.”

“Unfortunately, these figures are cause for outrage, not celebration,” Gabriel Sayegh of the Drug Policy Alliance said in a statement. “In this economy, Mayor Bloomberg and the NYPD are wasting millions of tax dollars by using illegal searches and false charges to sweep tens of thousands of black and Latino youth into the criminal justice system.” read more

WNYC reveals that serious issues continue with marijuana prohibition enforcement in the Big Apple:

“We are still seeing on a daily basis cases where our clients are being arrested and charged with misdemeanors where according to them, they never possessed marijuana in public view,” said Scott Levy, an attorney with the Bronx Defenders.  “They possessed it in their pocket, in their clothing.” read more

New York State legislators also took a strong step in June to bring New York City in line with the state’s existing marijuana decriminalization policy.  The new bill, SB5187/AB7620, remains active in Albany.

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. Questions?  [email protected]

Marijuana has a long-held reputation of “making you dumb.” This has been upheld by studies in the past that have discounted factors like gender and education (what?!)

But this recent study followed nearly 2,000 young Australian adults for eight years and found that marijuana has little long-term effect on learning and memory.

The idea that marijuana makes you dumb has long been embodied in the stereotype of the slow, stupid stoner, seen in numerous Hollywood movies and TV comedies and going unquestioned by much of American culture. But a new study says no: the researchers followed nearly 2,000 young Australian adults for eight years and found that marijuana has little long-term effect on learning and memory— and any cognitive damage that does occur as a result of cannabis use is reversible.

Participants were aged 20-24 at the start of the study, which was part of a larger project on community health.  Researchers categorized them as light, heavy, former or non-users of cannabis based on their answers to questions about  marijuana habits.

Light use was defined as smoking monthly or less frequently; heavy use was weekly or more often. Former users had to have not smoked for at least a year. Fully 72% of the participants were non-users or former users; 18% were light users and 9% were heavy current users. Prior studies have found that drug users do accurately report their consumption levels in surveys like this as long as anonymity is guaranteed and there are no negative consequences for telling the truth.

Read more: http://healthland.time.com/2011/07/19/study-marijuana-not-linked-with-long-term-cognitive-impairment/#ixzz1Sm2uHBps

7/17/2011 – Dr. Uri Napchan was lead author on a commentary published by the American Headache Society, which discussed the possibility of using synthetic cannabinoids or natural Cannabis for the treatment of headaches. Given what scientists know about how Cannabis works, marijuana-like compounds or synthetic cannabinoids may be a promising treatment for acute, refractory, or cluster headaches.

The authors warn that it is premature to make strong clinical recommendations as there are only a small number of case reports and surveys suggesting a possible benefit from Cannabis for headache treatment. The authors do point out that Cannabis is a Schedule I drug and there is dispute over its value in different medical conditions among experts. Therefore, the authors imply that synthesizing a new cannabinoid specifically for headaches could be the best approach. This new chemical drug would not have anything from the natural Cannabis plant.

In a strange turn of events these scientists (and others like them) could see their research on a collision course with politicians in the United States. Ironically, the compounds that have the best possibilities are being swiftly prohibited. Under an “emergency” measure the US Drug Enforcement Administration (DEA) moved several synthetic cannabinoids into the Schedule I category under federal laws.

Over the last year synthetic cannabinoids have been demonized in this country because of a new fad drug on the streets marketed as “K2″ or “Spice.” Although these packages sold as “incense” just as often contain synthetic opiates (that are still perfectly legal by the way), the cannabinoids are what public officials seem to rant about.

The compounds already targeted for prohibition, called JWH cannabinoids, were supposed to be the building blocks of a variety of promising research that should be explored further. They were regularly used in academic laboratories but are now much more difficult to obtain for legitimate research.

The authors of this study present a well-found notion of creating a non-psychotropic synthetic cannabinoid that could treat headaches. But while more states approve laws for whole-plant medical marijuana, even more are passing local laws banning synthetic cannabinoids. Politics alone could prove to be the most significant barrier for developing the science in this headache study.

Jahan Marcu is currently investigating the pharmacology of cannabinoid receptors. He was working at the California Pacific Medical Center Research Institute when exciting discoveries were made showing enhanced anti-cancer effects with THC and CBD from the Cannabis plant. The findings were published in the Journal of Molecular Cancer Therapeutics. In 2009 he received the Billy Martin Award from the International Cannabinoid Research Society (ICRS). Jahan is currently the vice-chair the Medical and Scientific Advisory Board at Americans for Safe Access (ASA). Questions?   Contact    [email protected]

DISCLAIMER: The views and opinions expressed are those of the author and do not necessarily represent any University, business or affiliates. While the information provided in this blog is from published scientific studies it is not intended to diagnose or treat any disease.

5/5/2011 – Recent scientific articles reviewed the ability of cannabis and cannabinoids to treat pain, especially neuropathic pain. This may be new hope for doctors who are struggling to treat these conditions. Clinical trials on humans using cannabis in various forms (smoked, extracts, oral THC, synthetic analogues) were reviewed by different research teams. Three recent reviews of those human trials demonstrate that cannabis and cannabinoids are effective for treating certain types of chronic pain with acceptable side effects.

A review on the treatments for HIV neuropathic pain concluded that, “evidence of efficacy exists only for capsaicin, smoked cannabis and rhNGF (nerve growth factor). However, rhNGF is clinically unavailable and smoked cannabis cannot be recommended as routine therapy (Phillips et al).”

Meaning, the only medications that have been shown to effectively alleviate HIV/AIDS neuropathic pain are not available on the market. Notably “smoked cannabis” was shown to be effective for the treatment of HIV neuropathy, a condition that affects more than 40% of the estimated 33 million people currently living with HIV.

A University of Pennsylvania research team published a similar review concluding that, “there is strong evidence for a moderate analgesic effect in peripheral neuropathic and central pain conditions, and conflicting evidence for their use in nociceptive pain. For spasticity, most controlled studies demonstrate significant improvement. Adverse effects are not uncommon with cannabinoids, though most are not serious and self-limiting.”

Last but not least, researchers from Canada concluded, that “overall the quality of trials was excellent. Fifteen of the eighteen trials that met inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared to placebo, several reported significant improvements in sleep. There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases (Lynch et al).”

This team from was from Dalhousie University Department of Anesthesia and Pain Medicine, Hospital for Sick Children, University of Toronto. The researchers go on to say, “this systematic review of 18 recent good quality randomized trials demonstrates that cannabinoids are a modestly effective and safe treatment option for chronic non-cancer (predominantly neuropathic) pain.”

Traumatic pain is scratching your arm, banging your thumb with a hammer or post-operative pain (surgery). But neuropathic pain is something completely different because it is generated by diseases (Multiple Sclerosis, HIV/AIDS, amputation) or as a side effect from medication toxicity. Essentially the brain begins sending pain signals out to the body for no reason. Patients say they experience it as a burning or shooting pain sensation in their hands and feet at first. Neuropathic pain often progresses to become much more intense. Opiates do not seem to have any impact in certain groups of patients. Many HIV/AIDS patients use cannabis therapy already today; anecdotal reports have been confirmed with successful results in top-quality clinical trials.

Read more science at Freedomisgreen.com

Inhaled Marijuana May Keep Brain Cancer in Remission

A Brief History of Cannabinoid Research

Jahan Marcu is currently investigating the pharmacology of cannabinoid receptors. He was working at the California Pacific Medical Center Research Institute when exciting discoveries were made showing enhanced anti-cancer effects with THC and CBD from the Cannabis plant. The findings were published in the Journal of Molecular Cancer Therapeutics. In 2009 he received the Billy Martin Award from the International Cannabinoid Research Society (ICRS). Jahan is currently the vice-chair the Medical and Scientific Advisory Board at Americans for Safe Access (ASA).   Contact:  science { at } freedomisgreen.com

DISCLAIMER: The views and opinions expressed are those of the author and do not necessarily represent any University, business or affiliates. While the information provided in this blog is from published scientific studies it is not intended to diagnose or treat any disease.

9/2/2011 – Several news sources offered conflicting reports that one of New Jersey’s first Alternative Treatment Centers for cannabis was going to start building a facility.

Fox29 in Philadelphia declared:

The Garden State’s first medical marijuana growing center is on its way to Chesterfield Township, Burlington County. Read full

But the local Burlington County Times found out that the plans were not so firm:

Representatives from a West Trenton-based alternative treatment center have informed officials that they’re scouting locations in the township for a growing facility, but have not named a specific location nor submitted a site plan application to the Planning Board.

Compassionate Care Foundation Inc. canceled plans to appear before the Township Committee several weeks ago and has not communicated since, said Mayor Larry Durr, acknowledging the many unanswered questions about the plan. Read full

Chesterfield is a rural, farming community near McGuire Air Force Base.

Gov. Christie’s administration removed plans for home delivery of medical marijuana. Unless that restriction is lifted, patients or a designated caregiver must go to an ATC to pick up medicine.

This isn’t the first time that Compassionate Care Foundation has run into location issues. In March the company had announced plans to build in Bellmawr, NJ. That was apparently shocking news the mayor and local officials, who eventually turned away the ATC.

Having a relationship with the local community was supposed to be an important part of the scoring process for the NJ ATC applicants.

A prominent member of Compassionate Care Foundation’s Board of Trustees, David Knowlton, was an acting Commissioner of the state Department of Health and Senior Services.  NJ DHSS is the oversight entity for the medical marijuana program. Knowlton was also a member of Chris Christie’s gubernatorial transition team.

In fact, three of the six ATCs have very close ties back to Governor Christie, who has stated many times that he does not like the safe access law.

Gov. Christie suspended the operations at all of the ATCs for several months. Then, at a widely covered press conference on July 19th, Christie promised that state-regulated cannabis would be available to patients by December 2011.

In order to reach that goal the ATCs would need to start growing in the next eight weeks. As of this writing, none of the six ATCs have confirmed a physical location.

One ATC, Greenleaf Compassion Center, has plans to build in Montclair, NJ. On the surface they seem to have the most local support. Former mayor Jerry Fried, Montclair State University and some sitting city council members have all backed the concept. Still, an actual location for Greenleaf has not been announced.

The New Jersey Compassionate Use Medical Marijuana Act was signed into law in January 2010. Since that time the underground cannabis market and secretive, personal cultivation remain the only points of access for NJ residents with qualifying medical conditions.

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. Questions?  [email protected]

7/25/2011 – Praise continues this week for NJ Governor Chris Christie’s decision to follow the compassionate use law and the state constitution, ending another delay for the medical cannabis program. Six Alternative Treatment Centers (ATCs) will now move forward with operations. But the type of system being attempted is an entirely new animal and the regulations have not been finalized.

Shunning the holistic approach to therapeutic marijuana, the Christie Administration has sanctioned a centralized “medical model” with severe limitations compared to other states. The result of this narrow scope may not be exactly what patients had in mind when they envisioned access.

Medical cannabis in the Garden State will not be served from glass cases that house nine strains of Indica buds or from shelves of carefully frosted cupcakes and brownies. Instead it will likely be served over a counter that looks exactly like a pharmacy in pill bottles full of homogenized, ground-up plant matter.

There are two levels of unique restrictions, first is the compassionate law itself: New Jersey legislators allowed the shortest list of qualifying medical conditions in the country, a monthly supply of just two ounces and cut out home cultivation. Last minute language also limited cannabis products to lozenges, topical creams and raw material.

The proposed rules from the Christie Administration are the next level. They created the nation’s first mandatory cannabis doctor registry, capped THC content at 10 percent and would stop the six ATCs from home delivery or growing more than three strains. Those are just the highlights.

The full regulations, over 100 pages of them, are so bad that they could hamstring the program. The executive suspension/un-suspension has overshadowed this important part of the process.

Patients have spent the last year testifying against the rules before committees at the Senate, Assembly and even the Department of Health and Human Services (DHSS). Physicians and potential ATC operators (even some of the winners) also criticized the worst of the new restrictions.

Hearing those concerns, the Legislature passed new resolutions with bi-partisan support. Stating that the regulations violated the true intent of the compassionate use law elected officials began a rare process to invalidate them.

The winning ATC proposals already conform to the draconian rules. The ATCs are led by political players from both parties teamed up with hand-picked executives from top-tier medical and pharmaceutical institutions. Big names drip from the resumes: Pfizer, Rutgers University, The Robert Wood Johnson Foundation, George Washington University Cancer Center, The National Transportation Safety Board.

The New Jersey ATCs are the best funded, most politically connected medical marijuana operations in America. Most of the NJ ATCs plan to spend tens of millions of dollars researching the plant and its component cannabinoids. Qualifying patients are not considered customers but are treated more like doctor-ordered participants in some sort of advanced medical experiment.

But even the ATCs want the limitations lifted on THC potency and plant variations. Right now DHSS could change the rules voluntarily or the Legislature could continue in their resolve to force a re-write. Presumably, some action must be taken in order for the ATCs to proceed as expeditiously as Gov. Christie is now directing.

Gov. Christie Allows Medical Marijuana, Regulations Still Need Work

Trenton – NJ Governor Chris Christie held a press conference on July 19, 2011 to address the status of the Compassionate Use Medical Marijuana Act. He has decided to reverse his suspension of the program and allow six Alternative Treatment Centers to move ahead with their operations.

After discussing the various intersections or conflicts between state and federal laws Christie said, “I have instructed the Commissioner of Health to move forward as expeditiously as possible to implement the [program].”

VIDEO: http://www.livestream.com/governorchrischristie/video?clipId=pla_a1a6bf2e-1630-4282-bb87-f28f93e72f9a&utm_source=lslibrary&utm_medium=ui-thumb

“We are happy that the governor is moving forward with the medicinal marijuana program,” said Ken Wolski, a registered nurse and executive director of the Coalition for Medical Marijuana New Jersey (CMMNJ). “Patients have suffered too long waiting for this,” said Wolski, “In thousands of cases patients in NJ have already died without the improvement in quality of life and relief of suffering that marijuana can bring.”

CMMNJ remains focused on a final set of rules for the program that will be workable. “We still have a number of concerns about the regulations put out by the DHSS for this program,” Wolski said, “The physician registry is unnecessary and will disqualify numerous patients.  Plus the cap on THC level is arbitrary and home delivery is not being permitted. These are all roadblocks to patient access that we hope the Christie Administration will reconsider.”

Some of the ATCs have expressed the same concerns. http://newyork.cbslocal.com/2011/03/07/nj-to-hold-hearing-on-medical-marijuana-rules/

Seriously ill New Jersey residents who would qualify under the law expressed surprise and measured hope at the governor’s change in rhetoric.

Jay Lassiter lives with HIV and has testified for better regulations in Trenton, “This is a small step in the right direction for New Jersey and I’m glad that Governor Christie has finally discovered a sense of urgency to help New Jersey residents with cancer and AIDS. I look forward to the day when I won’t be a criminal just for taking medical cannabis.”

Charles Kwiatkowski, a father of three, lives with multiple sclerosis and has been one of the most visible patient advocates in New Jersey. “It’s good and bad…all the restrictions,” Kwiatkowski said today. “But, I’ll believe it when I see it. So far it has been a really long, painful wait.”

[Editor’s Note – Freedomisgreen posts submitted content to the site. If you are interested in sending press releases, text or photos please contact [email protected] .]

Read more at Freedomisgreen.com

8/24/2011 – John Ray Wilson was taken into custody today at the Somerset County Courthouse. He will begin serving a 5-year prison sentence. The 38-year-old MS patient was found with seventeen cannabis plants in 2008.  After serving five weeks in prison in 2010, Wilson was allowed to remain with his family pending an appeal. The NJ Appellate Division upheld his conviction and sentence in late July. Wilson appeared before Superior Court Judge Angela Borkowski in a hearing today to consider a continuation of his bail.

Judge Borkowski ruled that her court was not an appropriate jurisdiction to deviate from the trial decision and appellate court affirmation. Any bail appeal should be made to the Appellate Division. Wilson’s attorney, William Buckman of Moorestown, said that he will file for bail immediately.

During the brief hearing the prosecutor, Deputy Attorney General Russell Curley, argued that Wilson should begin serving his sentence today. The judge agreed. John was taken into custody in the courtroom and is currently being held at the Somerset County jail.

“We think that the appellate decision is misguided,” said Wilson’s attorney William Buckman, “we are hoping that the Supreme Court will set the record straight that New Jersey doesn’t want to put sick people or simple individual marijuana users into prison at the cost of $35,000 a year.”

Buckman has filed a notice of petition to the Supreme Court to appeal the “manufacturing” conviction. The Appellate Division ruled that there was no consideration that the cannabis plants were only for Wilson’s “personal” use.

Ken Wolski, executive director of the Coalition for Medical Marijuana New Jersey (CMMNJ) was in the courtroom today.

“CMMNJ is still hopeful there is a chance for justice in the state Supreme Court. But we are very disappointed that John is back in jail.”

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. Questions?  [email protected]

8/9/2011 – John Ray Wilson is saying goodbye to his family. The 38 year old man lives with multiple sclerosis and without healthcare. Last month an appellate court ruled to uphold his 2010 conviction for “manufacturing” marijuana. He is now living in limbo as a judge considers his bail during a final appeal to the state Supreme Court. John may have to begin serving a 5-year prison sentence any day.

Wilson grew seventeen cannabis plants in the backyard of his Franklin Township home.  This was an effort to treat his condition. His trial in 2009/2010 took place at the same time as the final debates over the compassionate use act in the NJ legislature. Supporters demonstrated in front of the Somerville Courthouse. But the law was too late for John Wilson. 

John was never allowed to mention that he had MS or that he was growing for his own medical necessity. The state threw every heavy book they had at him. They attempted to convict on the first degree felony of “Operating and Maintaining a Controlled Dangerous Substance Manufacturing Facility.” This was a law designed for crack, meth and heroine processing mainly in urban environments.  A first degree felony would carry a mandatory minimum of 15 years in prison.

Multiple sclerosis is one of the few approved conditions under the NJ medical marijuana law. Dr. Denis Petro, a neurologist who testified before the legislature, was ready to offer expert testimony at Wilson’s trial about the unique benefits of cannabis on MS. But Petro and other experts were never allowed.

Medical quality marijuana is expensive on the underground market, $300-$500 per ounce. Home cultivation by medical marijuana patients is allowed in 14 of the 16 states with compassionate use laws. It is certainly a safe and economical way to find relief. Unless a helicopter comes hovering over.

When the NJ State Police Marijuana Eradication Unit arrived at his residence John was up front with officers and detectives. When they were called to the stand, the NJ State Police officers could not recall those conversations in the hours they spent sitting with John at a picnic table in his backyard.

I was in the courtroom the day John took the stand in his own defense. There was significant media attention on the trial from television and newspapers. The jury may have been aware of the reporters or the medical marijuana demonstrators holding signs in front of the courthouse each day. On December 17, 2009 the jury heard MS mentioned officially in the trial for the first time. Here’s my report from that day:

It was honest and sincere; it was the truth. On the stand in his own defense, John Wilson was allowed to tell the jury that he has Multiple Sclerosis.

“I told them I was not a drug dealer and I was using the marijuana to treat my MS.” John had been asked what he said to the State Police officers who arrived to investigate the 17 cannabis plants spotted by helicopter.

It seems Wilson has been truthful with law enforcement authorities about his intentions regarding the medical use of his marijuana from their first contact with him.

NBC 4 in NY was in the courtroom and correctly called the single-sentence event a “Stunning Reversal at Medical Marijuana Trial.” read full

In the end John was convicted on the second-degree felony of “manufacturing marijuana” as well as a third-degree felony for less than gram of psilocybin.

He was taken into custody for five weeks last spring, but was since allowed to remain with his family on bail. His appeal stated that he grew the cannabis for personal use. Under New Jersey law marijuana possession cases can often have the distribution charges removed if the person claims all of the pot was for personal use.

Because of the archaic terminology of “manufacturing” applied to cultivating marijuana, the appellate court ruled there could be no “personal use” defense applied.

The next step is an appeal to the NJ Supreme Court.

NJ Senators Raymond Lesniak and Nicholas Scutari both called on then-Governor Jon Corzine to pardon Wilson but to no avail. A similar petition will be made to Governor Chris Christie.

Like millions of working class Americans the Wilson family is struggling with a variety of serious health care costs.

John’s younger brother Kenny is a developmentally disabled adult bound to a wheelchair.  His grandmother endures the many burdens of aging. Even with the MS, John is still the healthier one and spends his days helping his family.  Working from home on an eBay store with his mom, John tries to make ends meet.

On the other side of his prison sentence Wilson hopes to be part of New Jersey’s medical marijuana program. But he may still face some hurdles. First the program is not yet running. More ominous is the real possibility that if John is granted parole he will face regular, mandatory drug testing. There is no medical marijuana exception to these probation and parole rules.

The approved operators of the first six medical cannabis Alternative Treatment Centers have been given a mandate by Governor Chris Christie to expedite their start-up. With millions of dollars in funding and top-level executives the ATCs are preparing to farm hundreds, even thousands of cannabis plants soon.

John Ray Wilson waits patiently yet has a great pressure on him each day. He is hopeful for the further appeal but has resigned himself to being separated from his family. John has prepared, as best as he can, to serve a prison term for growing the same medicine now regulated by the state.

There is a Facebook support page for John here

More about the John Wilson trial http://www.examiner.com/john-wilson-trial-in-philadelphia

Chris Goldstein is a respected marijuana reform advocate. As a writer and radio broadcaster he has been covering cannabis news for over a decade. Questions?  [email protected]